BUZZ - Bank of America downgraded the rating of Smithfield Foods to "Neutral," causing the stock price to drop
路透社2026/10/09 14:46October 9 – ** Smithfield Foods (SFD.O), a pork producer, saw its share price fall by 2%, closing at $18.51 ** Bank of America downgraded the stock from “buy” to “neutral,” and adjusted the price target from $25 down to $21 ** The brokerage cited deteriorating fundamentals in the hog industry: weak demand for pork belly and ham, declining lean hog futures prices, and persistently high feed costs have led to expectations of reduced hog profits ** They expect the packaged meats segment to remain stable and stated that a recovery in the hog industry or a significant rise in packaged meats profits would make them more optimistic about the stock ** Out of seven brokerages, four rate the stock “buy” or higher, and the remainder rate it “hold”; according to LSEG data, the median price target is $28 ** As of the previous trading day’s close, the stock is down approximately 15% year to date. (For convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translation may result in errors or lack necessary context, Reuters does not guarantee the accuracy of automatically translated texts, which are provided solely for readers’ convenience. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation features.)
October 9 - ** Shares of pork producer Smithfield Foods (SFD.O) fell 2% to $18.51
** Bank of America downgraded the stock from “Buy” to “Neutral,” and lowered the target price from $25 to $21.
** The brokerage said the fundamentals of the swine industry have deteriorated: demand for bacon and ham is weak, lean hog futures prices are declining, and with feed costs remaining high, expected hog profits are falling.
** The packaged meats business segment is expected to remain stable, and the brokerage said it would take a more optimistic view of the stock if the hog industry recovers or packaged meats profits show significant growth.
** Among seven brokerages, four rate the stock as “Buy” or higher, with the rest at “Hold”; the median target price is $28—data compiled by LSEG.
** As of the close of the previous trading day, the stock has fallen around 15% so far this year.
(To assist non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or not convey the intended context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for reader convenience. Reuters accepts no responsibility for any damage or losses caused by the use of the automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Market Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuts on the US stock market; shares fall over 10% after opening
As of press time, the stock has dropped more than 10%, trading at $10.77.
U.S. Stocks Move | Trex Bio (TRXB.US) Debuts on the U.S. Stock Market, Drops Over 1.3% After Opening
As of press time, the stock has fallen by over 1.3%, trading at $13.805.
BUZZ - Broker Perspectives: Analysts Express Doubts Over Starbucks and Chipotle Acquisition
Latest Update October 9 – The Financial Times reported on Thursday that Starbucks (SBUX.O) has explored a potential acquisition of Chipotle (CMG.N). This move would bring CEO Brian Niccol back to the Mexican burrito chain he once led. Starbucks declined to comment, saying the company remains "fully focused" on its business turnaround. Chipotle's stock fell about 4% to $31.32 on Friday, after surging 6.2% in the previous trading session. Limited strategic rationale BTIG expressed "high skepticism," stating that the deal does not make sense operationally, would cause significant dilution for Starbucks shareholders, and would disrupt management operations. "Over the years we've heard many stories about multi-brand acquisitions... but few have materialized, and even fewer have succeeded," BTIG noted. William Blair pointed out that Starbucks’ $9.4 billion net debt as of June makes it difficult to finance an acquisition and could push the combined company’s leverage ratio to about six times—considered high for the restaurant industry. D.A. Davidson stated the probability of the deal succeeding is 20% or less, given the significant differences between the brands and the apparent lack of clear synergies. Raymond James noted that due to the low overlap in menus, supply chain benefits are likely limited, while performance among multi-brand restaurant platforms has been mixed. eMarketer’s Suzy Davidkhanian commented that Niccol's familiarity may reduce execution risk, but investors might still see the deal as a "costly distraction" during Starbucks’ transformation. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Automated translation may be inaccurate or fail to include necessary context; Reuters does not guarantee the accuracy of automated translated text and provides it solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss resulting from the use of automated translation functions.)
BUZZ - UBS raises its target price for Biogen due to the catalyst in its late-stage R&D pipeline; stock price rises
October 9 - ** Shares of pharmaceutical company Biogen (BIIB.O) rose 2.4% to $223.71 ** UBS raised its price target from $240 to $270 and reiterated a "Buy" rating ** Third-quarter revenue is expected to reach $2.69 billion, with earnings per share (EPS) at $2.11, both slightly above market consensus ** Third-quarter sales of Alzheimer's drug Leqembi are predicted to be $200 million, in line with market expectations, and the recently launched subcutaneous formulation is projected to become a key growth driver starting in 2027 ** Biogen is now more optimistic about ophthalmology drug Syfovre than it was at the time of acquiring Apellis (link), and is optimizing its commercialization strategy ** Late-stage clinical data for lupus drug litifilimab due later this year and data on cutaneous lupus erythematosus expected in the first half of 2027 are seen as key catalysts ** Furthermore, late-stage clinical results for kidney drug felzartamab, expected in the first half of 2027, are anticipated to provide further upside, and clinical trials by Eli Lilly (LLY.N) for presymptomatic Alzheimer's may produce positive spillover effects ** Including intraday fluctuations, the stock is up 26.3% year-to-date.
Crypto prices
More
